Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Researchers from Mayo Clinic provide details of new studies and findings in the area of breast cancer
August 7th, 2008
According to a study from the United States, "For women with hormone receptor-positive disease, the third-generation aromatase inhibitors (AIs), anastrozole, letrozole, and exemestane, are more effective than tamoxifen in improving disease-free survival (DFS) when used initially or as adjuvant therapy following two to three years of tamoxifen or after tamoxifen has been completed. Demonstrating improvement in overall survival (OS), or breast cancer-associated mortality, however, requires long follow-up in large numbers of patients." "Subsequent crossover to another treatment following disease recurrence further confounds the assessment of OS benefit. DFS is the primary...
Source: Women's Health Weekly (2008-08-07)
|
